Drugs / dimethyl sulfoxide
dimethyl sulfoxide
also known as
DMSO · Dimethylsulfoxyde · Dimetil sulfoxido · Infiltrina · NSC-763 · Rimso 50 · SQ 9453 · Syntexan
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | RIMSO-50 | — | 1978-04-04 | fda.gov ↗ |
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03103594 | Aug 2015 → Aug 2016 | urinary bladder disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT00118313 | Nov 2004 → Jul 2006 | cutaneous melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07567274 | May → Jul 2026 overdue | tinnitus | Leading Edge Clinic | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT03716583 | Apr 2019 → Jan 2021 | breast cancer, radiodermatitis | Dennis Bregner Zetner | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02206477 | Aug 2014 → Dec 2017 | — | Rabin Medical Center | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05187494 | May → Aug 2021 | — | Damascus University | Completed | No outcome recorded |
| — | NCT01074567 | Dec 2009 → Dec 2011 | interstitial cystitis | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00317070 Comparator | Apr 2006 → Feb 2009 | interstitial cystitis | Nova Scotia Health Authority | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT05223244 Comparator | Oct 2011 → Apr 2019 | interstitial cystitis | Endeavor Health | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07196618 Comparator | Sep 2025 → Feb 2026 overdue | — | Al-Azhar University | Active not recruiting | No outcome recorded |
| — | NCT01069263 Comparator | Feb 2010 → Mar 2015 | interstitial cystitis | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dimethyl sulfoxide | “Compounded otic liquid containing dimethyl sulfoxide (DMSO) 50% (v/v), betahistine dihydrochloride 8 mg/mL, dexamethasone sodium phosphate 0.2 mg/mL, and lidocaine hydrochloride 1%.” NCT07567274 ↗7“Dimethyl sulfoxide (DMSO) is an FDA-approved treatment for BPS and is thought to work by its exceptional solvent properties.” NCT03103594 ↗ |
| Known as | Dimethylsulfoxyde | ChEMBL registry synonym — accepted as the source's own label CHEMBL504 ↗ |
| Known as | Dimetil sulfoxido | ChEMBL registry synonym — accepted as the source's own label CHEMBL504 ↗ |
| Known as | DMSO | “will administer approximately 1 g of cream containing melatonin (25 mg/g) and dimethyl sulfoxide (DMSO) (150 mg/g) or a placebo cream topically twice daily on the irradiated skin area” NCT03716583 ↗7“Compounded otic liquid containing dimethyl sulfoxide (DMSO) 50% (v/v), betahistine dihydrochloride 8 mg/mL, dexamethasone sodium phosphate 0.2 mg/mL, and lidocaine hydrochloride 1%.” NCT07567274 ↗ “Intravesical Dimethyl Sulfoxide (DMSO)” NCT00317070 ↗ “dimethyl sulfoxide (DMSO)” NCT05223244 ↗ |
| Known as | Infiltrina | ChEMBL registry synonym — accepted as the source's own label CHEMBL504 ↗ |
| Known as | NSC-763 | ChEMBL registry synonym — accepted as the source's own label CHEMBL504 ↗ |
| Known as | Rimso 50 | ChEMBL registry synonym — accepted as the source's own label CHEMBL504 ↗ |
| Known as | SQ 9453 | ChEMBL registry synonym — accepted as the source's own label CHEMBL504 ↗ |
| Known as | Syntexan | ChEMBL registry synonym — accepted as the source's own label CHEMBL504 ↗ |
| Modality | Small molecule | — CHEMBL504 ↗ |
| Route | Other | “Patients receive vaccine therapy comprising MP, TET, GM-CSF, and dimethyl sulfoxide TD on days 1, 8, and 15.” NCT00118313 ↗ |